Cel Sci (CVM) Change in Accured Expenses (2010 - 2026)
Cel Sci (CVM) posted Change in Accured Expenses of -$26240.0 for Q1 2026, up 88.41% sequentially from -$226360.0 in Q4 2025, and down 8.21% YoY from -$28585.8 in Q1 2025.
Cel Sci (CVM) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Cel Sci has reported Change in Accured Expenses for 16 years, with the latest figure at -$26240.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 8.21% year-over-year to -$26240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92331.0 (up 86.66% YoY) and the FY2025 annual result came in at $120728.0, up 126.33% from the prior year.
- Change in Accured Expenses rose to -$26240.0 in Q1 2026 per CVM's latest filing, from -$226360.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $845755.0 in Q2 2025 and troughed at -$685486.0 in Q3 2025.
- A 5-year average of -$42963.2 and a median of -$24250.0 in 2025 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1634.39% in 2025, down 1380.35% in 2025.
- Over 5 years, Change in Accured Expenses stood at $79087.0 in 2022, then tumbled by 111.28% to -$8924.0 in 2023, then sank by 71.35% to -$15291.0 in 2024, then sank by 1380.35% to -$226360.0 in 2025, then soared by 88.41% to -$26240.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$26240.0, -$226360.0, and -$685486.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -7,099.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26,240.00 |
| Mar 31, 2026 | -26,240.00 |
| Dec 31, 2025 | -226,360.00 |
| Dec 31, 2025 | -226,360.00 |
| Sep 30, 2025 | -685,486.00 |
| Sep 30, 2025 | -685,486.00 |
| Jun 30, 2025 | 845,755.00 |
| Jun 30, 2025 | 845,755.00 |
| Mar 31, 2025 | -24,250.00 |
| Mar 31, 2025 | -24,250.00 |
| Dec 31, 2024 | -15,291.00 |
| Dec 31, 2024 | -15,291.00 |
| Sep 30, 2024 | -597,732.00 |
| Sep 30, 2024 | -597,732.00 |
| Jun 30, 2024 | -55,120.00 |
| Jun 30, 2024 | -55,120.00 |
| Mar 31, 2024 | 203,287.00 |
| Mar 31, 2024 | 203,287.00 |
| Dec 31, 2023 | -8,924.00 |
| Dec 31, 2023 | -8,924.00 |